Study: Fluoroquinolone Stewardship Programs Work, but Effect Wanes at Discharge
Hospitals that try to discourage the use of fluoroquinolones succeed at lowering prescriptions for patients admitted to the hospital, but many of those patients still leave with prescriptions for fluoroquinolones at discharge.
Stewardship programs designed to reduce the use of fluoroquinolones work, but a new study finds the programs don’t do enough to curb prescriptions at discharge.
With antibiotic overuse a continuing concern at US hospitals, investigators from the University of Michigan wanted to find out whether hospital-based programs designed to limit prescribing of fluoroquinolones were having the desired effect. Their findings were published last month in Clinical Infectious Diseases. Fluoroquinolones (including ciprofloxacin, levofloxacin, and moxifloxacin) have been associated with severe adverse events and are believed to contribute to antibiotic resistance.
To study the question, the investigators constructed a retrospective study of 11,748 patients who were admitted to 48 hospitals with either pneumonia or a positive urine culture between December 2015 and September 2017. The 48 hospitals were surveyed to find out whether they had a stewardship program aimed at controlling fluoroquinolone antibiotics. The vast majority—96%—of hospitals had an antibiotic stewardship program, but only a fraction included fluoroquinolones.
“We found that at the time of data collection (Fall 2016), 29% of hospitals used 1 of 2 core stewardship strategies (pre-prescription approval and/or prospective audit and feedback) to target fluoroquinolone prescribing,”
Valerie Vaughn, MD, MSc
corresponding author Valerie Vaughn, MD, MSc, told Contagion® in an interview.
Hospitals that targeted fluoroquinolone prescribing had lower rates of fluoroquinolone prescriptions for pneumonia and UTIs compared to those without fluoroquinolone stewardship programs (37.1% versus 48.2%). This translated to 2282 days on fluoroquinolones per 1000 patients at hospitals with stewardship programs versus 3096 days on fluoroquinolones per 1000 patients at hospitals without stewardship programs.
That’s the good news. There was also some bad news.
The investigators wrote that the programs “had an attenuated association with aggregate fluoroquinolone exposure.” Overall exposure to fluoroquinolones was not affected by stewardship programs in patients with positive urine cultures, despite US Food and Drug Administration guidance that the drugs should be avoided for uncomplicated UTIs unless no other options are available.
Among patients with pneumonia, fluoroquinolone stewardship programs did lower prescribing rates, although Dr. Vaughn and colleagues said these patients were still being prescribed fluoroquinolones at too high a rate.
Adding to the bad news, the study showed that stewardship programs didn’t seem to have an effect on prescriptions at discharge; many patients who weren’t given the drugs while admitted to the hospital were switched to them when they were released. Dr. Vaughn said there are likely a few different reasons for this.
One problem, she said, is that stewardship programs tend to center chiefly on initial prescriptions.
“This is what disease-based guidelines focus on (e.g., when to add coverage for MRSA),” she said. “But guidelines, both nationally and then locally, place less emphasis on de-escalation, transition to oral, and discharge.”
This problem could be fixed if recommendations were amended to include discharge. Another problem, though, is that it can be difficult for health care organizations to track discharge prescriptions.
“The discharge script is sent to another pharmacy, not well-documented, or phoned-in/hand-written and almost impossible to track,” Dr. Vaughn said. “So many stewardship programs don’t even know what’s happening at discharge.”
This is less of a problem when hospitals fill the patients’ prescription at internal pharmacies, which is what happens with Veterans Administration hospitals. However, Dr. Vaughn said most health systems will likely need a different approach to improve their tracking of discharge prescriptions.
Although more needs to be done to curb fluoroquinolone prescriptions at discharge, Dr. Vaughn said more and more hospitals seem to be paying attention to their use of this class of antibiotics. She noted that in 2017 the Joint Commission began requiring antibiotic stewardship programs as a condition of hospital accreditation. That change has led more hospitals to start or expand antibiotic stewardship programs. She added that a survey of hospitals in the Michigan Hospital Medicine Safety Consortium shows that more hospitals are including fluoroquinolones in their stewardship programs.
Dr. Vaughn said there are several easy steps hospitals can take to get a grip on fluoroquinolone prescribing.
“First, ensure that institutional disease-specific guidelines discuss options for de-escalation to oral and transition to discharge, trying to move providers away from fluoroquinolones when possible,” she said. “This should start with urinary tract infection and pneumonia, since these 2 diseases are so common and infectious diseases providers are often not involved.”
Hospitals should also incorporate discharge recommendations into their normal provider education programs and ensure that their hospital-wide stewardship programs account for discharge prescriptions.
“If, for example, your hospital is already performing antibiotic timeouts, make sure that the timeout includes a plan for discharge prescribing,” she said.
Asked what she would say to hospital leaders who are reticent to prioritize fluoroquinolone stewardship, Dr. Vaughn said she hopes these new data will help make the case. She also noted that fluoroquinolone stewardship is also an important way to curb Clostridium difficile infection.
“Leadership is often moved by discussion of C difficile,” she said, “so this is a great place to start.”